Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 18 of 25
Conjugated Hyperbilirubinemia and Pulse Oximetry
NCT00741117
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
NCT01434459
Test-Retest Reliability in DETECT
NCT01733641
Study of Arsenic Trioxide in Small Cell Lung Cancer
NCT01470248
Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
NCT01378117
Vitamin D in Ventilated ICU Patients
NCT01372995
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
NCT01331161
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
NCT01395407
The Energy Dose Study
NCT01369147
DPP-4 Inhibition and TZD for DM Prevention
NCT01006018
Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury
NCT01730443
The Health Access and Recovery Peer Program
NCT01725815
Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery
NCT01361594
Phenylketonuria, Oxidative Stress, and BH4
NCT01395394
Exercise Intolerance in Renal Failure
NCT01356966
Decision-Making in Bipolar Disorder
NCT01463111
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
NCT01331135
Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting
NCT01366469
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
NCT01138371
Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass
NCT01352143
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
NCT01334710
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
NCT01240200
The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias
NCT01373424
Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
NCT01733056
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
NCT01228318
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
NCT01283334
RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery
NCT01283321
Intermittent Hypoxia Elicits Prolonged Restoration of Motor Function in Human SCI
NCT01272349
Hypofractionated Radiotherapy in Breast Cancer
NCT03167359
Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI
NCT01272336
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
NCT01272141
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
NCT01270321
A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment
NCT01283269
Botulinum Toxin in the Treatment of Raynaud's
NCT01233999
Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
NCT01232868
Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis
NCT01020045
Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
NCT01218542
Study of Everolimus (RAD001) in Combination With Lenalidomide
NCT01218555
The Effectiveness of Lubiprostone in Constipated Diabetics
NCT01170039
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
NCT01337713
Couples HIV Counseling and Testing for Male Couples in the United States
NCT01861210
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
NCT01319851
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
NCT01230788
Etanercept and Vascular Function in Psoriasis
NCT01989689
Phenotype Depression Study
NCT01426997
Re-expression of ER in Triple Negative Breast Cancers
NCT01194908
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
NCT01005979
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
NCT01188109
Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging
NCT01129635
NMDA Receptors in Motor Learning in Humans
NCT02082912
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.